[Pulmonary fibrosis in rheumatic diseases].
Rheumatic diseases are frequently complicated by secondary pulmonary diseases, which often impair the quality of life and increase the mortality of patients. A correct classification of such pulmonary complications is important to ensure appropriate treatment and optimal prognosis. The diagnostic and therapeutic challenge is to find the precise diagnosis and appropriate therapy among the multitude of potential causes for respiratory symptoms. It is important to maintain a cautious approach to invasive diagnostics, even though the differential diagnostics of infections or toxic lung disease might be crucial. The situation is further complicated by the frequent lack of evidence for therapies. Especially in the case of pulmonary fibrosis which is comparable to cancer in its complexity and high mortality, the diagnostics and therapy should be discussed in appropriate interdisciplinary boards.
Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
D
D
Grund
Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. elise.siegert@charite.de.
E
E
Siegert
D003937:Diagnosis, Differential; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D011658:Pulmonary Fibrosis / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D012216:Rheumatic Diseases / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D018570:Risk Assessment / Q000379:methods; D016896:Treatment Outcome
Histology; Imaging; Immunosuppression; Interstitial lung disease; Therapy